Knowledge Content Library
203
Drug Delivery Devices - A Decision Analysis
Presented by Alfons Lieftucht and Lee Hodge (GlaxoSmithKline) at 2005 DAAG Conference in Philadelphia. Illustration of importance of getting metrics right in a drug delivery example.
continue to: decisionprofessionals.com
204
Factored stochastic tree modeling for medical decision making
Presented by Gordon Hazen (Northwestern University) at 2005 DAAG Conference in Philadelphia. Example using stochastic trees - decision trees with stochastic nodes - applied to a drug problem.
continue to: decisionprofessionals.com
206
How to win friends and influence deal terms
Presented by Ajoy Chakrabarti (BristolMyersSquibb) at 2005 DAAG Conference in Philadelphia. Discussion of licensing problem for an oncology drug.
continue to: decisionprofessionals.com
207
Modeling the global latent therapeutic demand for hemophilia A
Presented by Jeff Stonebreaker (GlaxoSmithKline) and Donald Keefer (Arizona State University) at 2005 DAAG Conference in Philadelphia. Shows model based on probability-encoding principles and discrete approximation techniques to estimate global latent therapeutic demand for hemophilia A using population-based epidemiology and treatment modalities.
continue to: decisionprofessionals.com
141
Incorporating Learning Models in Structuring and Valuing R&D Projects
Presented by Phil Beccue (Baxter) at 2004 DAAG Conference in San Francisco. Real options example using decision trees for evaluation of "learning models".
continue to: decisionprofessionals.com
142
Back of the Envelope Analysis
Presented by Harry Eckerson and David Swank (GlaxoSmithKline) at 2004 DAAG Conference in San Francisco. Example of how to do a quick analysis when time is insufficient for more detailed work, using sensitivity and what-if analyses.
continue to: decisionprofessionals.com
145
Decision Analysis to Evaluate Clinical Proof-of-Principle Trial Design for a New Drug
Presented by Vish Viswanathan and Rick Bayney (Johnson & Johnson) at 2004 DAAG Conference in San Francisco. Example of value of information approach to evaluation of a trial design decision.
continue to: decisionprofessionals.com
148
Pharmaceutical Portfolio Management
Presented by Kazuo Ezawa (BristolMyersSquibb) at 2004 DAAG Conference in San Francisco. Discussion of pharmaceutical industry challenges and how those challenges are dealt with in portfolio planning and analysis.
continue to: decisionprofessionals.com
150
Strategy Evaluation for a Pharmaceutical Oncology Asset
Presented by Erik C. Johnson (BristolMyersSquibb) at 2004 DAAG Conference in San Francisco. Case study of decision analysis of oncology drug development, and the unique characteristics of evaluating these types of drugs.
continue to: decisionprofessionals.com
385
Application of Attrition to Resource Forecasts
Presented by Bill Reid (GlaxoSmithKline) at 2003 DAAG Conference in Houston. This talk discusses a method of accounting for attrition in portfolio planning which uses information normally readily available and models attrition the way it happens.
380
Are You Sure Your Proof of Concept Studies Add Value?
Presented by David Swank and Lee Hodge (GlaxoSmithKline) at 2003 DAAG Conference in Houston. Provides and overview of value-of-information methods applied to proof-of-concept studies in pharma.
continue to: decisionprofessionals.com
135
Global Optimization of Portfolio: Therapeutic Area Considerations
Presented by Vish Viswanathan (Johnson & Johnson) at 2003 DAAG Conference in Houston. Illustrates importance of considering dependencies in portfolio analysis, including those due to economies of scale and scope.
136
Managing an R&D Portfolio Process in Real Time
Presented by Jay Andersen (Eli Lilly) at 2003 DAAG Conference in Houston. Discussion of changing the portfolio process from the usual cyclic update to being able to update real time as needed.
137
Value-Driven Portfolios
Presented by James Felli (Eli Lilly) at 2003 DAAG Conference in Houston. Discusses one method of portfolio construction that allows an organization’s goals to be mapped directly into an appropriate set of relative measures to facilitate the determination of an optimal mix of portfolio elements.
138
Life Cycle Management as a Portfolio: A Case History
Presented by D. Charlesworth (Decision Strategies) at 2003 DAAG Conference in Houston. Discusses how a combination of portfolio analysis and project tools were successfully used with a multi-discipline team to quickly develop a life cycle management strategy for a recently launched compound.
111
Decision Analysis Application and Patterns at Boehringer Ingelheim
Presented by Jessica Hayden and Jim Keirns (Boehringer Ingelheim) at 2002 DAAG Conference in Las Vegas. Discussion of processes at BP and how they add value to the organization.
continue to: decisionprofessionals.com
113
Patterns in Pharma DA - An Example from Abbott Labs
Presented by Steven Kuemmerle (Abbott Labs) at 2002 DAAG Conference in Las Vegas. Discussion of DA processes and value drives at Abbott Labs.
continue to: decisionprofessionals.com
115
Determining the Value of an Asset for Portfolio Selection
Presented by Rick Bayney (BristolMyersSquibb) at 2002 DAAG Conference in Las Vegas. Discussion of portfolio analysis where there are technical and commercial dependencies among projects.
continue to: decisionprofessionals.com
120
Implementation of DA Projects: Three Fables
Presented by Stuart Harris (GlaxoSmithKline) at 2002 DAAG Conference in Las Vegas. Presents three examples of decisions in GSK, with a somewhat humorous take on the outcomes and lessons learned.
continue to: decisionprofessionals.com
122
2-Dimensional Policy Sensitivity Diagrams Convey Concise Insights
Presented by Phil Beccue (Amgen) at 2002 DAAG Conference in Las Vegas. Examples of how to plot 2-way sensitivity analysis to reveal optimal policy choices under different assumptions.
continue to: decisionprofessionals.com